Axsome Therapeutics Inc (NASDAQ: AXSM) on Monday, soared 5.58% from the previous trading day, before settling in for the closing price of $98.06. Within the past 52 weeks, AXSM’s price has moved between $64.11 and $139.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 96.67% annually for the last half of the decade. The company achieved an average annual earnings per share of 47.22%. With a float of $40.08 million, this company’s outstanding shares have now reached $48.67 million.
In an organization with 683 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 90.89%, operating margin of -73.11%, and the pretax margin is -74.45%.
Axsome Therapeutics Inc (AXSM) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Axsome Therapeutics Inc is 17.82%, while institutional ownership is 77.67%. The most recent insider transaction that took place on Feb 13 ’25, was worth 1,558,320. In this transaction Chief Financial Officer of this company sold 12,000 shares at a rate of $129.86, taking the stock ownership to the 42,187 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Financial Officer sold 3,000 for $131.07, making the entire transaction worth $393,210. This insider now owns 42,187 shares in total.
Axsome Therapeutics Inc (AXSM) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 47.22% per share during the next fiscal year.
Axsome Therapeutics Inc (NASDAQ: AXSM) Trading Performance Indicators
Axsome Therapeutics Inc (AXSM) is currently performing well based on its current performance indicators. A quick ratio of 2.04 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.00, a number that is poised to hit -1.31 in the next quarter and is forecasted to reach 2.26 in one year’s time.
Technical Analysis of Axsome Therapeutics Inc (AXSM)
Let’s dig in a bit further. During the last 5-days, its volume was 1.23 million. That was better than the volume of 0.95 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 45.93%. Additionally, its Average True Range was 6.38.
During the past 100 days, Axsome Therapeutics Inc’s (AXSM) raw stochastic average was set at 44.00%, which indicates a significant decrease from 45.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.34% in the past 14 days, which was higher than the 57.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $119.38, while its 200-day Moving Average is $97.46. However, in the short run, Axsome Therapeutics Inc’s stock first resistance to watch stands at $105.93. Second resistance stands at $108.33. The third major resistance level sits at $112.45. If the price goes on to break the first support level at $99.42, it is likely to go to the next support level at $95.30. The third support level lies at $92.90 if the price breaches the second support level.
Axsome Therapeutics Inc (NASDAQ: AXSM) Key Stats
Market capitalization of the company is 5.05 billion based on 48,765K outstanding shares. Right now, sales total 385,690 K and income totals -287,220 K. The company made 118,770 K in profit during its latest quarter, and -74,910 K in sales during its previous quarter.
